Loading...
We zouden het geweldig vinden als je deel wordt van onze community. Word lid van onze Discord om met ons en andere leden in contact te komen!
- Ticker
- MVIR.ST
- Price
- 0.55
- Stock movement down
- -0.10 (-5.03%)
- Company name
- Medivir AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Marktkapitalisatie
- 207.74M
- Ent waarde
- -
- Prijs/Verkoop
- -
- Prijs/Boek
- -
- Div opbrengst
- -
- Div groei
- -
- Jaren van groei
- -
- FCF-uitkering
- -
- Trailing P/E
- -
- Toekomstige P/E
- -
- PEG
- -
- EPS-groei
- -
- 1 jaar rendement
- -38.68%
- 3 jaar rendement
- -38.00%
- 5 jaar rendement
- -31.30%
- 10 jaar rendement
- -30.66%
Laatst bijgewerkt: 2025-09-17
DIVIDENDEN
MVIR.ST keert geen dividend uit
WAARDERING
Waarderingsverhoudingen
Loading...
Gegevens over waarderingsratio's
| Trailing P/E | - |
| Prijs tot OCF | - |
| Prijs tot FCF | - |
| Prijs tot EBITDA | - |
| EV tot EBITDA | - |
Waardering (verkoop/boekwaarde)
Loading...
Waarderingsgegevens (verkoop/boekwaarde)
| Prijs tot verkoop | - |
| Prijs te boeken | - |
| EV naar verkoop | - |
FINANCIËN
AANDELENINFORMATIE
Voorraadgrafiek
Loading...
Koersgegevens
| Open | 1.97 |
| Dagelijks hoog | 2.00 |
| Dagelijks laag | 1.85 |
| Dagelijks volume | 182K |
| Hoogtepunt aller tijden | 190.06 |
| 1y analistenraming | 18.71 |
| Beta | -0.30 |
| WPA (TTM) | - |
| Dividend per aandeel | 0.00 |
| Ex-div datum | - |
| Volgende inkomsten datum | 6 Nov 2025 |
Negatief potentieel
Loading...
Nadeel potentiële gegevens
| MVIR.ST | S&P500 | |
| Huidige prijsdaling vanaf het hoogste punt ooit | -99.71% | -0.20% |
| Hoogste prijsdaling | -99.35% | -19.00% |
| Datum van hoogste daling | 7 Apr 2025 | 8 Apr 2025 |
| Gemiddelde daling vanaf de top | -75.66% | -2.76% |
| Gemiddelde tijd tot nieuwe high | 407 days | 5 days |
| Max tijd tot nieuwe hoogte | 6471 days | 89 days |
BEDRIJFSGEGEVENS
Marktkapitalisatie
207.74M
Marktkapitalisatie categorie
Small-cap
Beschrijving
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat HDAC inhibitor for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. It has a collaboration and supply agreement with Eisai to evaluate fostrox, a liver-targeted treatment, in combination with lenvatinib for the treatment of liver cancer. The company was incorporated in 1987 and is based in Huddinge, Sweden.
Werknemers
10
Website
Investeerdersrelaties
-
SEC-dossiers
CEO
Land
Sweden
Stad
Type aandeel
-
CCC-status
-
Dividendfrequentie
-
EVENEMENTEN EN PRESENTATIES
EvenementenPresentaties
Loading...
HET BEDRIJF BEGRIJPEN
Loading...
BEDRIJFSNIEUWS
Alle nieuwsPersberichten
Medivir AB (STU:MVR0) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Medivir AB (STU:MVR0) reports promising clinical developments and patent extensions, while navigating funding hurdles to sustain its innovative pipeline.
22 augustus 2025
STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusin...
20 augustus 2025
The European market has shown mixed performance recently, with the pan-European STOXX Europe 600 Index remaining flat over a four-day period, while major indexes such as France's CAC 40 and Italy's FT...
9 juli 2025
As European markets continue to navigate a landscape marked by mixed performances and hopes for easing trade tensions, investors are increasingly seeking opportunities in less conventional areas. Penn...
15 mei 2025
Amid escalating trade tensions and the lowest consumer sentiment in nearly three years, European markets have experienced notable volatility. Despite these challenges, the concept of penny stocks rema...
16 april 2025
As European markets navigate the complexities of U.S. trade tariffs and monetary policy uncertainties, the pan-European STOXX Europe 600 Index recently saw a slight decline. Despite these challenges, ...
18 maart 2025
Medivir AB (FRA:MVR0) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Medivir AB (FRA:MVR0) reports significant progress in liver cancer treatment development, despite facing increased clinical costs and market competition.
19 februari 2025
Global markets have recently experienced mixed performances, with major stock indexes showing a combination of gains and declines as the year closed out. For investors looking beyond traditional blue-...
6 januari 2025